Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast
21 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report...
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research
20 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) - - Data to...
Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference
07 févr. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
Voyager Therapeutics Announces Pricing of Public Offering
04 janv. 2024 22h45 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of...
Voyager Therapeutics Announces Proposed Public Offering
04 janv. 2024 16h14 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has...
Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief...
Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies
02 janv. 2024 07h00 HE
|
Voyager Therapeutics, Inc.
- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy - - Voyager to receive up-front consideration of...
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
06 déc. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
06 nov. 2023 16h01 HE
|
Voyager Therapeutics, Inc.
- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development...
Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
30 oct. 2023 07h00 HE
|
Voyager Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today...